Skip to content

Investigator

Wade William Sugden

VERSITI BLOOD HEALTH, INC. · funded by NIDDK

Companies
1

Resolved onto their grants.

Grants
3

Federal awards on file.

Non-dilutive funding
$439k

Summed across those awards.

First award
Jul 1, 2021

Latest Feb 5, 2026.

Companies from this work

Pre-ticker companies the crosswalk resolved onto a grant filed under this investigator. Momentum shows for the therapeutic areas your seat covers; open a dossier for the full crosswalk.

Grant record

Federal awards filed under this investigator name, newest first. Each links to the public record where the awarding agency publishes one.

  1. R03

    Role of Force-directed Lipid Metabolism in the Endothelial-to-Hematopoietic Transition

    $128k

    Feb 5, 2026NIDDKVERSITI BLOOD HEALTH, INC.NIH RePORTER · 11286660 (opens the source filing in a new tab)

  2. K01

    Mechanisms of Flow-driven Transcriptional Control of Hematopoietic Stem Cell Development by YAP

    $153k

    Jul 1, 2021NIDDKBOSTON CHILDREN'S HOSPITALNIH RePORTER · 11061293 (opens the source filing in a new tab)

  3. K01

    Mechanisms of Flow-driven Transcriptional Control of Hematopoietic Stem Cell Development by YAP

    $158k

    Jul 1, 2021NIDDKVERSITI BLOOD HEALTH, INC.NIH RePORTER · 11354992 (opens the source filing in a new tab)

This page aggregates public U.S. federal grant records filed under one investigator name and the companies Biodatica has resolved onto them. Names are shown as the awarding agency filed them; grant awards are non-dilutive federal funding, not equity or valuation. Distinct people who file under the same name would appear together here. It is informational only and not investment advice. Methodology · Data sources